Podcasts about cometriq

  • 5PODCASTS
  • 13EPISODES
  • 3mAVG DURATION
  • ?INFREQUENT EPISODES
  • Jul 20, 2015LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about cometriq

Latest podcast episodes about cometriq

FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Monday, July 20, 2015

FirstWord Pharmaceutical News

Play Episode Listen Later Jul 20, 2015 2:25


GRACEcast
RET in Lung Cancer: The Next Big Target?

GRACEcast

Play Episode Listen Later Jul 7, 2015 3:32


A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

GRACEcast Lung Cancer Video
RET in Lung Cancer: The Next Big Target?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jul 7, 2015 3:32


A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

GRACEcast ALL Subjects audio and video
RET in Lung Cancer: The Next Big Target?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jul 7, 2015 3:32


A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

GRACEcast
Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks

GRACEcast

Play Episode Listen Later Jul 5, 2015 2:58


A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.

GRACEcast Lung Cancer Video
Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks

GRACEcast Lung Cancer Video

Play Episode Listen Later Jul 5, 2015 2:58


A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.

GRACEcast ALL Subjects audio and video
Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jul 5, 2015 2:58


A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.

GRACEcast
Cabozantinib for Late Stage Kidney Cancer

GRACEcast

Play Episode Listen Later Aug 12, 2014 2:38


Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.

GRACEcast Kidney Cancer Video
Cabozantinib for Late Stage Kidney Cancer

GRACEcast Kidney Cancer Video

Play Episode Listen Later Aug 12, 2014 2:38


Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.

GRACEcast ALL Subjects audio and video
Cabozantinib for Late Stage Kidney Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 12, 2014 2:38


Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.

GRACEcast Lung Cancer Video
What's the Status and Potential Utility of Cabozantinib in Lung Cancer?

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 17, 2014 3:22


Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.

GRACEcast
What's the Status and Potential Utility of Cabozantinib in Lung Cancer?

GRACEcast

Play Episode Listen Later Apr 17, 2014 3:22


Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.

GRACEcast ALL Subjects audio and video
What's the Status and Potential Utility of Cabozantinib in Lung Cancer?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 17, 2014 3:22


Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.